This article has been updated to include a statement from Myriad Genetics.

NEW YORK (GenomeWeb) – Law firm Sterne, Kessler, Goldstein & Fox announced today it has filed petitions for Inter Partes Review (IPR) with the US Patent and Trademark Office on behalf of its client GeneDx, which is seeking to nullify patents held by competitor Myriad Genetics related to gauging cancer risk based on mutations in three genes: BRCA1, BRCA2, and MUTYH.